Blue light can reduce blood pressure

Exposure to blue light decreases blood pressure, reducing the risk of developing cardiovascular disease, a new study from the University of Surrey and Heinrich Heine University Dusseldorf in collaboration with Philips reports. During this study, published in the prestigious European Journal of Preventative Cardiology, participants were exposed to 30 minutes of whole-body blue light at approximately 450 nanometres, a dose comparable to daily sunlight - followed by exposure to a control light on a different day. Visible blue light, as opposed to ultraviolet (UV) light, is not carcinogenic. To assess the impact, participants' blood pressure, stiffness of arteries, blood vessel dilation and blood plasma levels of nitric oxide stores were measured before, during, and up to two hours after irradiation with both lights.

Researchers discovered that exposure to whole-body blue light significantly reduced the systolic blood pressure of participants by almost 8 mmHg, compared to the control light which had no impact. The reduction of blood pressure from blue light is similar to what is seen in clinical trials with blood pressure lowering drugs.

Besides blood pressure lowering effects, it was also uncovered that exposure to blue light improved other cardiovascular risk markers including reduction of arterial stiffness and increasing blood vessel relaxation. This further supports that light could be used to prevent cardiovascular disease, which kills over 150,000 people in the UK every year.

Researchers also found that exposure to blue light increased levels of nitric oxide which is an important signalling molecular that protects the cardiovascular system. It is believed that blue light releases from the skin into the blood stream where it relaxes the blood vessels, increasing blood flow and decreasing blood pressure.

Christian Heiss, Professor of Cardiovascular Medicine at the University of Surrey and NHS consultant, said: "Exposure to blue light provides an innovative method to precisely control blood pressure without drugs. Wearable blue light sources could make continued exposure to light possible and practical. This would be particularly helpful to those whose blood pressure is not easily controlled by medication, such as older people."

Manuel Stern, Melanie Broja, Roberto Sansone, Michael Gröne, Simon S Skene, Joerg Liebmann, Christoph V Suschek, Matthias Born, Malte Kelm, Christian Heiss.
Blue light exposure decreases systolic blood pressure, arterial stiffness, and improves endothelial function in humans.
European Journal of Preventive Cardiology, 25(17), 1875–1883. doi: 10.1177/2047487318800072

Most Popular Now

Forxiga receives positive EU CHMP opinion for the …

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a new indication for the marketing authorisation of Forxi...

US FDA grants Breakthrough Therapy Designation for…

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Ther...

New pill can deliver insulin

An MIT-led research team has developed a drug capsule that could be used to deliver oral doses of insulin, potentially replacing the injections that people with type 2 di...

Merck to expand US biopharmaceutical R&D facil…

Merck, a leading science and technology company, today announced a $70 million investment to expand its state of the art research and development (R&D) facility in Biller...

Pfizer receives positive CHMP opinion for Vizimpro…

Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending V...

Cannabinoid compounds may inhibit growth of colon …

Medical marijuana has gained attention in recent years for its potential to relieve pain and short-term anxiety and depression. Now, Penn State College of Medicine resear...

Merck Granted U.S. Patent for novel combination of…

Merck, a leading science and technology company, today announced that it has been granted Patent No. US 10,193,695 by the United States Patent and Trademark Office (USPTO...

Simple drug combination creates new neurons from n…

A simple drug cocktail that converts cells neighboring damaged neurons into functional new neurons could potentially be used to treat stroke, Alzheimer's disease, and bra...

The Union for International Cancer Control and Pfi…

In conjunction with World Cancer Day, the Union for International Cancer Control (UICC) and Pfizer Inc. announce the third round of the Seeding Progress And Resources for...

Pfizer and Lilly announce top-line results from se…

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients...

Merck and Tencent announce collaboration on intell…

Merck, a leading science and technology company, signed a strategic collaboration agreement with Tencent, a leading provider of Internet value added services. The collabo...

New insight into cell receptors opens the way for …

New research on how cancer mutations influence a certain type of receptor on the cell membrane opens the way for the development of tailored drugs for certain cancers, su...